Choi, Yejoo Shin, Sungho Son, Hyo Jin Lee, Na-Hee Myeong, Su Hyeon Lee, Cheolju Jang, Hyemin Choi, Soo Jin Kim, Hee Jin Na, Duk L. 2024-01-19T09:04:05Z 2024-01-19T09:04:05Z 2023-08-17 2023-07 1757-6512 https://pubs.kist.re.kr/handle/201004/113503 BackgroundPreclinical studies showed that mesenchymal stem cells (MSCs) ameliorate tau phosphorylation, amyloid-beta accumulation, and inflammation in Alzheimer's disease (AD) mouse models via secretion of neurotrophic factors and cytokines. We aimed to identify CSF biomarkers that can be used to predict or monitor the response to MSCs in patients with AD.MethodsAD patients were injected with human umbilical cord blood-MSCs (n = 22) or placebo (n = 12). The cerebrospinal fluid (CSF) samples were collected at baseline, one day after the first injection, and one day after the third injection. The patients injected with MSCs were classified into good responder (GR) or poor responder (PR) groups based on the rate of changes in the ratio of total-tau and phosphorylated-tau in the CSF. We selected three typical participants in each group, and their CSF protein levels were analyzed using liquid chromatography/tandem mass spectrometry (LC-MS/MS).ResultsIn the LC-MS/MS analysis, 1,667 proteins were identified. Eleven proteins showed significant differences between the typical GR and PR at baseline. Based on their significance level and known functions, two proteins, reticulocalbin-3 (RCN3) and follistatin-related protein 3 (FSTL3), were selected as potential biomarkers to predict MSC response. A total of 173 proteins showed significant change one day after the third injection compared to the baseline in typical GR. We excluded 45 proteins that showed significant change after the third injection compared to the baseline in the typical PR. Based on their significance level and known function, four proteins, scrapie-responsive protein 1 (SCRG1), neural proliferation differentiation and control protein (NPDC1), apolipoprotein E (ApoE), and cystatin C (CysC), were selected as potential biomarker to monitor MSC response. Additionally, functional analysis revealed that the increased CSF proteins after the third injection compared to the baseline in the typical GR were associated with synaptogenesis.ConclusionsThis study identified two proteins (RCN3 and FSTL3) that may be potential biomarkers for predicting MSC response and four proteins (SCRG1, NPDC1, ApoE, CysC) that may be potential biomarkers for monitoring MSC response in patients with AD. Further studies are needed to validate our results.Trial registration Clinical Trials.gov, NCT02054208. Registered on 4 February 2014. Samsung Medical Center IRB File No.2017-04-025. Registered on 20 June 2017. English BioMed Central Identification of potential biomarkers related to mesenchymal stem cell response in patients with Alzheimer's disease Article 10.1186/s13287-023-03410-8 1 Stem Cell Research & Therapy, v.14, no.1 Stem Cell Research & Therapy 14 1 Y scie scopus 001032116800001 2-s2.0-85165325886 Cell & Tissue Engineering Cell Biology Medicine, Research & Experimental Cell Biology Research & Experimental Medicine Article APOLIPOPROTEIN-E ACTIVIN-A ASSOCIATION WORKGROUPS DIAGNOSTIC GUIDELINES NATIONAL INSTITUTE CYSTATIN-C U2 SNRNP EXPRESSION BINDING GENE Alzheimer&apos s disease Mesenchymal stem cell LC-MS MS Biomarker